Pot firms gain as US move to ease curbs lifts sentiment
Reuters
Published Aug 31, 2023 09:31
(Reuters) - U.S.-listed shares of marijuana companies rose up to 7% in premarket trading on Thursday after the Department of Health and Human Services recommended reclassification as a lower-risk substance following an 11-month review.
Marijuana remains illegal at the federal level even as nearly 40 U.S. states have legalized its use in some form, and the reclassification is seen as the first step toward wider legalization that has the support of a majority of Americans.
"Certainly moving cannabis off of Schedule 1 is the right decision and long overdue. Though a full descheduling would be preferred and likely most appropriate for cannabis," said Patrick Rea, managing director of venture capital firm Poseidon Garden Ventures.
The firm held investments in companies like retailer and producer Green Thumb Industries, and cannabis data platform Flowhub, according to its website.
Shares of cannabis firms SNDL, OrganiGram Holdings (TSX:OGI), Tilray (TSX:TLRY) Brands, Cronos Group (TSX:CRON), Canopy Growth (TSX:WEED) and Aurora Cannabis (TSX:ACB) rose between 1.2% and 7%.
Pot stocks tracker AdvisorShares Pure US Cannabis ETF gained 3.7% premarket. It closed 21.2% higher on Wednesday, clocking its best day since Oct. 6, 2022.
The recommendation was provided to the Drug Enforcement Agency who has the final authority on rescheduling and will now initiate its own review.
Still, some analysts said the rescheduling would not be able to address the banking or capital market access challenges for cannabis companies.
The SAFE Banking Act, a crucial legislation that would make it easier for the cannabis industry to access banking services, has failed to secure a Senate vote despite the House passing it seven times.
"The main issue the industry will face revolves around the crucial fact that over the last two decades, dozens of states have developed their own cannabis laws (medical or recreational) in the absence of cohesive federal regulation. And rescheduling to Schedule III would not solve this mismatch," Bernstein analyst Nadine Sarwat said.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.